Is the GRAIL Galleri Blood Test Worth It? What to Know Before You Get Screened

The Short Answer

The GRAIL Galleri test is a blood test that screens for signals from more than 50 cancer types using DNA fragments that tumors shed into your bloodstream. At ASCO 2026, the first randomized trial of any test like it, the NHS-Galleri trial, reported results worth understanding precisely before you decide anything.

What it didn’t show: the trial’s main goal (reducing combined Stage III and Stage IV diagnoses) was not achieved. There was no statistically significant difference between the screened and unscreened groups.

What it did show: a planned secondary analysis, limited to twelve pre-specified cancer types, found Stage IV diagnoses fell 14% overall across three years of annual screening, with the effect growing stronger each round: 9% in year one, 22% in year two, 26% in year three. Only the year-three result reached statistical significance on its own.[3]

What it costs: $949 out of pocket. Most insurers and Medicare don’t cover it.

What it doesn’t replace: colonoscopy, mammography, or any other standard-of-care screening you’re already due for.

Who it’s actually for: adults 50 and older with elevated risk (significant family history, a prior cancer, or a cancer type with no established screening protocol) who are current on standard screening and want a physician-coordinated way to add surveillance for what existing tests can’t catch.

Opening

If you’ve read the PATHFINDER abstracts, compared Galleri to the panels offered by Function Health or Superpower, and are trying to decide whether to get tested, the question worth answering is whether this test would change anything for you, and what you’d actually do with a positive or negative result. Here’s what the evidence supports, what it doesn’t, and how to think about both before you spend nearly $1,000 on a blood draw.

What the Test Can and Cannot Tell You

Every day, cells throughout your body shed small fragments of DNA into your bloodstream, a material researchers call circulating cell-free DNA (cfDNA), most of which comes from ordinary cell turnover. Tumor cells shed cfDNA too, and their DNA carries distinctive chemical modifications called methylation patterns, molecular markers that identify which tissue a fragment came from and whether it behaves like a cancer cell.

Galleri reads those markers, using next-generation sequencing to scan your cfDNA and screen for signals across more than 50 cancer types. When it detects a signal, it predicts the cancer signal origin (CSO), the likely tissue source. In the final PATHFINDER results published in The Lancet, the refined version of the test reported CSO accuracy of approximately 88% and a positive predictive value of 43.1%, meaning that when the test returned a positive result, roughly 43% of those results reflected a confirmed cancer.[1]

Unlike somatic mutations, which can appear in normal aging cells as well as malignant ones, cancer-specific methylation patterns tend to be distinctive to tumor tissue, which is why Galleri uses methylation rather than mutation detection alone. A more precise molecular signature is not the same as a complete one.

A positive result is not a diagnosis; it means the test detected a cancer signal and in most cases suggests a probable tissue of origin, pointing toward a diagnostic workup (imaging, endoscopy, biopsy) that may or may not confirm a malignancy. In PATHFINDER, 92 of 6,621 participants (approximately 1.4%) had a positive result; 35 of those 92 (roughly 38% in the initial version, 43% in the refined version) turned out to have confirmed cancer. The rest underwent a workup that found nothing, a stressful experience that is easy to underestimate before you’ve been through it.[1]

A negative result doesn’t rule out cancer, either. Across cancer types in the foundational CCGA validation study, overall sensitivity was 51.5%, with Stage I sensitivity of just 16.8%.[2] A negative Galleri means the test didn’t detect a signal at this point in time, not a confirmation that no cancer is present.

The specificity figure of approximately 99.5% across published studies sounds reassuring until you work through the arithmetic.[1,2]  “This is where patients understandably get confused,” says Jay Luthar, MD, DipABLM, founder of Lutanen Health and faculty at Harvard Medical School. “A 99.5%-specific test still produces false positives. In a population where cancer prevalence is roughly 1%, a meaningful share of positive results will not turn out to be cancer. That isn’t a flaw unique to Galleri — it’s how screening math works. The conversation before the test is as important as the result itself.” 

That pre-test conversation about what a positive or negative result would actually mean for you, given your specific history, is the clinical work that separates a physician-ordered Galleri from a flag in an app.

What the NHS Galleri Trial Actually Showed at ASCO 2026

The NHS Galleri trial, presented by Swanton et al. at ASCO 2026 (Abstract LBA100), was the first randomized controlled trial of any multi-cancer early detection test, embedded within the National Health Service and enrolling approximately 142,000 participants.[3] Unlike the single-arm PATHFINDER study, this trial had a control arm, which is what allows the Stage IV finding below to carry more weight than a single-arm observational result could. As of publication, the full results have not been published in a peer-reviewed journal; reference [3] below cites the conference abstract.

The primary endpoint was not met. The trial’s primary outcome was a reduction in combined Stage III and Stage IV cancer diagnoses across twelve pre-specified cancer types, and the screened arm did not achieve a statistically significant reduction in that composite: IRR 1.03, p = 0.63.[3] Initial press coverage of the ASCO 2026 presentation sometimes led with the secondary finding and buried this primary result, which is worth correcting because a trial is powered to detect its primary endpoint, not its secondary ones.

A meaningful secondary finding. The pre-specified secondary analysis of Stage IV diagnoses alone, limited to those same twelve cancer types, showed a 14% reduction across all three screening rounds combined, with the effect strengthening at each round: 9% after the first round, 22% after the second, 26% after the third.[3] Only the third-round reduction reached statistical significance on its own; the second round’s confidence interval crossed 1.0. That pattern of strengthening effect with each additional round of annual screening is consistent with how stage-shifting is expected to behave if the test is doing what it’s designed to do, but it remains a secondary and still-developing signal rather than a confirmed population-level benefit.

“The NHS data are genuinely encouraging, and they have to be read carefully,” says Julia Loewenthal, MD, co-physician at Lutanen Health. “The trial didn’t meet its primary endpoint, and that matters. But the Stage IV secondary finding, in a randomized design, is the kind of signal that moves a technology from ‘interesting’ to ‘worth a serious clinical conversation with selected patients’ — not for everyone, and not instead of standard screening, but alongside it for people whose risk profile makes sense.” 

What the trial doesn’t yet tell you. Stage-shifting is a surrogate endpoint, and overall survival data from the NHS trial aren’t mature yet; GRAIL has announced plans to extend follow-up by six to twelve months to capture mortality outcomes.[3] Whether Galleri ultimately saves lives is not answered by any currently published data. Two methodological concerns are worth holding alongside the positive findings: length-time bias (screening preferentially detects slower-growing tumors, which can inflate apparent benefit) and overdiagnosis (detecting cancers that would never have caused clinical harm in your lifetime). Neither has been fully characterized in the MCED literature yet. The downstream workup burden (imaging, endoscopy, and procedures triggered by positive results) was acknowledged in the ASCO 2026 reporting as an “other impact” alongside short-term anxiety, but was not quantified in a formal subanalysis; GRAIL has indicated that cost-benefit analyses are planned as part of continued follow-up.[3]

Where things stand regulatorily. Galleri is not FDA-approved as a cancer screening test. The FDA’s 2024 LDT final rule, which would have subjected tests like Galleri to device-style FDA oversight, was vacated by the U.S. District Court for the Eastern District of Texas on March 31, 2025, and formally rescinded by FDA on September 19, 2025 (90 FR 45134, FR Doc. 2025-18239, Docket No. FDA-2025-N-1730).[4] As of publication, laboratory-developed tests including Galleri operate under CLIA/CMS laboratory standards. USPSTF has not issued any recommendation on Galleri or any MCED test as of June 2026.[5] CMS doesn’t cover Galleri for Medicare beneficiaries as a screening test outside of the REACH study, a Medicare-embedded comparative prospective cohort study designed to generate the evidence base for potential future coverage.[6]

Galleri vs. Standard-of-Care Screening: What Each Does and Doesn’t Cover

The most common misunderstanding about Galleri is that it competes with or replaces the guideline-recommended screening you’re already doing. The tests below are guideline-recommended, often insurance-covered, and for their specific targets have significantly better sensitivity at early stages than any MCED test currently available. Galleri is designed to add surveillance for cancers these tests don’t cover, not to substitute for any of them.

Galleri’s particular value lies in the cancers for which no established population-level screening protocol exists: pancreatic, ovarian outside high-risk programs, hepatocellular, and certain rare malignancies. These are precisely the cancers that tend to present at Stage IV when diagnosed through symptoms alone, which is where an imperfect but earlier signal has the highest potential to change outcomes.

If you’ve completed your standard-of-care screening and want an additional layer of surveillance, particularly for hard-to-screen cancers, the clinical rationale is coherent. If you’re not current on your colonoscopy or mammogram, starting there first is the evidence-based standard.

Who Is This Test Actually For? A Concrete Profile

The evidence supports specificity in patient selection. Here’s the kind of situation where adding Galleri to a comprehensive screening program has a defensible clinical rationale — not a guarantee of benefit, but a meaningful incremental signal.

Picture a 56-year-old executive whose father was diagnosed with colorectal cancer at 58 and whose mother had ovarian cancer at 62. He’s current on colonoscopy, clear two years ago, and his wife completed a CA-125 and transvaginal ultrasound through a high-risk program. He has no established screening protocol for pancreatic cancer, a malignancy that killed a colleague at 59 with no warning, and his concern is specifically the cancers that have no early detection standard. What he’s looking for is comprehensive surveillance of the gaps standard screening leaves.

If that’s close to your situation, a single conversation with a portal-based service won’t serve you well. You need a physician who knows your full history, can frame the actual pre-test probability of a positive result given your specific risk factors, and, if Galleri returns a CSO signal pointing toward pancreatic or hepatic origin, can move quickly and directly to the right specialist.

Both Function Health and Superpower now reference liquid biopsy or multi-cancer panels in their testing menus; what neither currently offers is the physician coordination that follows a positive result: who calls the gastroenterologist, who orders the MRCP, who interprets an ambiguous finding on an endoscopic ultrasound, and who sits with you through the weeks between a frightening result and a definitive answer. In PATHFINDER, the median time to diagnostic resolution after a positive Galleri was approximately 79 days,[1] nearly three months in which having a physician coordinate the workup is a material difference, one that is difficult to quantify in advance and easy to underestimate until you need it.

Patient Story

A patient in her early 60s, a physician herself with a demanding clinical schedule and a strong family history of gastrointestinal malignancies, came to Lutanen Health for executive health services after relocating to the Boston area. Her standard-of-care screening was fully current: colonoscopy clear, mammography negative, LDCT negative (she had a remote smoking history). She approached the conversation analytically rather than anxiously, and she wanted to know what else was reasonable.

After a full review of her history and a conversation about what Galleri’s sensitivity and false-positive rates meant in practical terms for someone at her risk level, she decided to proceed. The result came back with a cancer signal detected, CSO pointing toward a gastrointestinal origin. The next five days involved a direct referral to a gastroenterologist within the MGB network (no waiting on hold, no navigating a referral form), followed by an MRI and then an EUS. The EUS identified a small lesion that was biopsied and confirmed as a very early mucinous neoplasm, surgically resectable. She had surgery within six weeks of her Galleri result.

The moment she’s most grateful for, she says, was not the positive test result itself but the phone call from her physician the day the result came in, before she had read it in a portal, explaining exactly what it meant and what would happen next.

What the Repeat-Testing Commitment Actually Looks Like

GRAIL recommends annual testing, which reframes the “is it worth it?” question in a way the headline alone doesn’t. A test at $949 repeated annually over ten years is a nearly $10,000 commitment, one that is not prohibitive for most patients this piece is written for, but real enough to weigh seriously alongside the clinical case.

The clinical rationale for annual repeat testing is that cancer biology is dynamic: a tumor shedding cfDNA below the detection threshold this year may cross that threshold next year. Annual cadence is designed to maximize the chance of catching a signal while a cancer is still early and treatable. Whether that cadence should change as the evidence matures, or as your own risk profile changes, is a conversation that belongs in a physician relationship rather than a testing portal.

How Lutanen Health Approaches MCED Screening

The Lutanen Health approach to Galleri and multi-cancer early detection is a clinical process rather than a menu item. It begins with risk stratification: before any MCED test is ordered, a full review of your personal and family cancer history, prior screening results, genetic risk data where available, and relevant biomarkers establishes whether Galleri adds meaningful incremental information for you specifically. For most patients under 50 with average risk, it doesn’t.

Standard-of-care screening is confirmed current before Galleri enters the conversation. The test isn’t ordered as a substitute for colonoscopy, mammography, LDCT, or any other guideline-recommended screening, and if you’re overdue on any of these, that gets addressed first. What follows, assuming Galleri is appropriate, is pre-test counseling: the specificity math, the stage-sensitivity limits, the false-positive rate, and what a positive result actually triggers, discussed in enough detail that you can meaningfully consent to what comes next rather than simply agreeing to a blood draw.

Galleri sits within a broader surveillance program that may include germline genetic testing, polygenic risk scores, relevant tumor marker panels, and imaging where appropriate. If you have significant family history, genetic counseling and BRCA or Lynch syndrome testing through Ambry Genetics (in-network with most U.S. health plans and typically covered for patients meeting family-history criteria) are addressed as a prior or parallel step in the workup.

If a positive CSO signal does occur, the workup that follows is coordinated directly by Lutanen Health physicians within the MGB network, with referrals made and timelines actively tracked so you’re not navigating the process alone. Whether to repeat Galleri annually, modify that cadence, or shift to a different surveillance approach entirely gets reviewed at each annual executive health visit, in the context of everything else that’s changed in your overall clinical profile since the prior result.

If you’re 50 or older, have a significant family history of cancer (particularly GI, ovarian, pancreatic, or other malignancies without established population-level screening), and are current on standard-of-care screening, the conversation about whether Galleri adds value to your program is worth having. Become a member or learn more about our approach to early detection and executive health.

Frequently Asked Questions 

Is the Galleri test FDA-approved? 

No. Galleri is not FDA-approved as a cancer screening test. The FDA’s 2024 LDT final rule, which would have imposed device-style premarket oversight on laboratory-developed tests, was vacated by a federal court in March 2025 and formally rescinded by the FDA in September 2025. As of publication, Galleri operates under CLIA/CMS laboratory standards. USPSTF has not issued a recommendation on any MCED test.[4,5]

Does Medicare cover the Galleri test? 

No, not as a standard benefit. CMS does not cover Galleri for Medicare beneficiaries outside of the REACH study, a Medicare-embedded comparative prospective cohort study. Eligible Medicare beneficiaries may be able to enroll in REACH to receive the test at no cost within the study.[6] 

Can the Galleri test replace my colonoscopy or mammogram? 

No. Galleri does not replace colonoscopy, mammography, lung CT screening, or any other guideline-recommended test. For the cancers those tests target, they have substantially better sensitivity at early stages than Galleri. Galleri is designed to complement them, particularly for cancer types without established population-level screening protocols. 

What happens if my Galleri result is positive? 

A positive result is not a diagnosis. It means a cancer signal was detected, along with a predicted tissue of origin. It triggers a diagnostic workup (typically imaging, and potentially endoscopy or biopsy) to determine whether cancer is present. In the PATHFINDER study, the refined Galleri test had a positive predictive value of approximately 43%, meaning a positive result was confirmed as cancer roughly 43% of the time. The median time to diagnostic resolution was approximately 79 days[1] — a period that requires active physician coordination.

What if my Galleri result is negative? 

A negative result significantly lowers, but does not eliminate, concern for cancer. The test’s overall sensitivity was 51.5% across cancer types in the foundational CCGA study, with Stage I sensitivity of 16.8%.[2] Standard-of-care screening should continue on its normal schedule regardless of a negative Galleri result. 

How much does the Galleri test cost, and how often should it be repeated? 

The out-of-pocket cost is $949. GRAIL recommends annual testing. Most commercial insurers do not cover it as of publication. Some flexible spending accounts (FSAs) and health savings accounts (HSAs) may allow it as an eligible expense — confirm with your plan administrator. 

Who should consider the Galleri test? 

Adults 50 and older with elevated cancer risk are the most clearly defined population. Elevated risk includes significant family history (particularly of cancers diagnosed before age 60, or of cancers with no established screening protocol), personal history of prior cancer or cancer-predisposing genetic variants, or substantial occupational or environmental exposure history. It is not indicated for the general population under 50 and is not a substitute for guideline-recommended screening at any age. 

How is Galleri different from what Function Health or Superpower offers? 

Function Health and Superpower offer broad laboratory panels, some of which include cancer-related biomarkers or reference liquid biopsy testing. What distinguishes a physician-ordered Galleri at a practice like Lutanen Health is not the test itself (the same GRAIL kit is drawn) but what happens before and after: risk-stratified pre-test counseling, integration with your full medical history and genetic data, and direct physician coordination of any diagnostic workup that follows a positive result. A CSO signal pointing toward pancreatic origin deserves a gastroenterologist referral within days, not a notification in an app.

Key Takeaways

The GRAIL Galleri test is the most carefully studied multi-cancer early detection blood test available, and the NHS Galleri trial at ASCO 2026 produced the first randomized data in the field. Those data are genuinely encouraging in their secondary Stage IV findings, read precisely: a 14% overall reduction across twelve pre-specified cancers, growing to 26% by the third screening round, with only that third-round result reaching statistical significance on its own. They have to be read alongside the fact that the primary endpoint wasn’t met, that the full trial results have not yet been published in a peer-reviewed journal, and that survival data aren’t available yet.

For the right patient (50 or older with elevated cancer risk, current on all guideline-recommended screening), Galleri is a defensible addition to a comprehensive surveillance program: appropriate for a defined subset, not inexpensive, and best understood as the beginning of a clinical process rather than a conclusion.

Learn more about how Lutanen Health approaches advanced diagnostics and early cancer detection, or explore what’s included in executive health membership.

References

1. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251–1260. doi: 10.1016/S0140-6736(23)01700-2. PMID: 37805216.

2. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167–1177. doi: 10.1016/j.annonc.2021.05.806.

3. Swanton C, et al. NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening. ASCO Annual Meeting, Abstract LBA100, May 30, 2026, Chicago. Conference abstract; as of June 2026, full results have not been published in a peer-reviewed journal.

4. FDA. Medical Devices; Laboratory Developed Tests; Implementation of Vacatur. 90 FR 45134 (Sept. 19, 2025). FR Doc. 2025-18239. Docket No. FDA-2025-N-1730. Available at: https://www.federalregister.gov/d/2025-18239.

5. U.S. Preventive Services Task Force. USPSTF A and B Recommendations. Available at: https://www.uspreventiveservicestaskforce.org. [Note: No recommendation issued on multi-cancer early detection tests as of June 2026.]

6. GRAIL, Inc. Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare) Study. NCT05673018. Comparative prospective cohort study of Galleri in the Medicare population. Available at: https://clinicaltrials.gov/study/NCT05673018.